DAY 3 - Tuesday, June 28, 2011

Greetings from the American Diabetes Association’s 71^st Scientific Sessions

The editorial staff of Medical Economics brings you daily coverage of breaking news, the latest research findings, and reports of interest to the readers of Medical Economics, Drug Topics, Formulary, and Contemporary OB/GYN.

Our four-day coverage of this year’s American Diabetes Association’s 71st Scientific Sessions includes the results of major clinical trials and ongoing news and information of interest to clinicians who treat type 1 and 2 diabetes.

BREAKING NEWS

Preventing diabetes with metformin is cost saving, while lifestyle intervention is also cost effective

William H Herman, MD, MPH

Lifestyle intervention is cost effective, and metformin therapy is actually cost saving in the prevention of type 2 diabetes, said William H Herman, MD, MPH. These economic data were derived from a 10-year cost analysis as a follow-up to the landmark Diabetes Prevention Program (DPP).» MORE

NEW RESEARCH

SGLT2 inhibitor has durable antihyperglycemic effect, genital infections more common

Dapagliflozin, an investigational selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, has durable efficacy in controlling blood glucose as add-on therapy to metformin with a low risk of hypoglycemia, said Clifford J. Bailey, MD, Professor of Clinical Science at Aston University in Birmingham, UK.» MORE

Coronary artery calcium levels predict CVD mortality in type 2 diabetes

Subhashish Agarwal, MD

Coronary artery calcification is a “striking” independent predictor of cardiovascular mortality in patients with type 2 diabetes, said investigators.» MORE

CLINICAL TRIALS

Adding insulin detemir to metformin/liraglutide further lowers HbA_1c in type 2 diabetes patients not achieving control with oral therapy

A treatment-intensification sequence starting with liraglutide added to metformin followed by adding basal insulin detemir further improves glycemic control with a low risk of hypoglycemia in patients who don’t reach their hemoglobin (Hb) A_1c target on metformin plus liraglutide, reported Julio Rosenstock, MD.» MORE

Topical clonidine reduces pain level in diabetic neuropathy

A topical clonidine gel applied to the site of pain in patients with painful diabetic neuropathy reduced the level of pain in those patients with intact nociceptors in the skin, said James N Campbell, MD.» MORE

Type 1 diabetes leads to carotid artery stiffness in young adults

Elaine M Urbina, MD

Type 1 diabetes can lead to internal carotid artery thickness and common carotid artery stiffness, and this effect is measurable by the time a person with diabetes reaches young adulthood, reported Elaine M Urbina, MD, Director of Preventive Cardiology at Cincinnati Children’s Hospital in Cincinnati, Ohio.
» MORE

PATIENT MANAGEMENT

DPP-4 inhibitors, GLP-1 receptor agonists reduce hypoglycemia risk

Increased risk for hypoglycemia appears to be inevitable with intensive glycemic control in patients with type 2 diabetes, but there are steps that clinicians can take to minimize the risk, said Gabriele Perriello, MD, PhD, from the Department of Internal Medicine at the University of Perugia, Italy.» MORE

Intensive glycemic control not associated with more falls or fractures in older patients

Older adults with type 2 diabetes who follow intensive glycemic control practices are not at increased risk for falls or fractures compared with patients who follow standard glycemic control, despite a higher incidence of hypoglycemia in the former, reported investigators who analyzed data from the ACCORD BONE study.» MORE

Medical Economics is pleased to share this ADA conference coverage with the readers of:

From the conference floor

We welcome your feedback!
Please send your comments to:
Medical Economics editorial staff
medec@advanstar.com